Read by QxMD icon Read

Journal of Cancer Research and Clinical Oncology

A Abendroth, R Noureddine, M Abramczyk, A Paul, G Gerken, K W Schmid, P Markus, B Schumacher, M Wiesweg, J Köhler, M Markus, B Mende, A Dechêne, M Schuler, S Kasper
INTRODUCTION: Patients (pts) with locally advanced (LAPC) or metastatic pancreatic ductal adenocarcinoma (mPDAC) have a dismal prognosis. Recently, new combination chemotherapies such as FOLFIRINOX and nab-paclitaxel/gemcitabine have demonstrated superiority over gemcitabine monotherapy. However, a substantial proportion of pts cannot tolerate these intensive front-line protocols. Moreover, the long-term superiority of multiagent protocols over less intensive strategies remains to be shown...
November 14, 2018: Journal of Cancer Research and Clinical Oncology
Jihao Zhou, Qi Shen, Haiqing Lin, Lina Hu, Guoqiang Li, Xinyou Zhang
PURPOSE: Multiple myeloma (MM) remains incurable. The MM microenvironment supports MM cells' survival and immune escape. Because myeloid-derived suppressor cells (MDSCs) is important in the MM microenvironment, and demethylating agent decitabine (DAC) can deplete MDSCs in vitro and in vivo, we hypothesized that DAC treatment could inhibit MM by depleting MDSCs in the MM microenvironment. METHODS: In this study, we used the mouse IL6 secreting, myeloma cell line MPC11 as a model...
November 13, 2018: Journal of Cancer Research and Clinical Oncology
Christina K Cramer, Natalie Alphonse-Sullivan, Scott Isom, Linda J Metheny-Barlow, Tiffany L Cummings, Brandi R Page, Doris R Brown, Arthur W Blackstock, Ann M Peiffer, Roy E Strowd, Stephen Rapp, Glenn J Lesser, Edward G Shaw, Michael D Chan
INTRODUCTION: Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30-50% of irradiated brain tumor survivors. In preclinical models, pioglitazone prevents RICD but there are little safety data on its use in non-diabetic patients. We conducted a dose-escalation trial to determine the safety of pioglitazone taken during and after brain irradiation. METHODS: We enrolled patients > 18 years old with primary or metastatic brain tumors slated to receive at least 10 treatments of RT (≤ 3 Gy per fraction)...
November 12, 2018: Journal of Cancer Research and Clinical Oncology
Tingting Guo, Junyao Li, Lin Zhang, Wei Hou, Rongrong Wang, Jie Zhang, Peng Gao
PURPOSE: Non-coding RNAs (ncRNAs) have been a hot topic for many years in the field of cancer research, especially miRNAs and lncRNAs. Because they play critical roles in regulating various cellular processes and are more often involved in tumorigenesis than protein-coding genes. But the cross talk between miRNAs and lncRNAs in cancer has been scarcely studied. This article aims to provide a retrospective review of the latest research on the link between miRNAs and lncRNAs in lung cancer and discusses their potential role as diagnostic biomarkers and therapeutic targets for lung cancer in clinical practice...
November 11, 2018: Journal of Cancer Research and Clinical Oncology
Tao Xie, Bing Liu, Chun-Gang Dai, Zhao-Hui Lu, Jun Dong, Qiang Huang
PURPOSE: This study aimed to examine whether the different tumor-transplanted sites could construct a similar immunoinflammatory microenvironment and to investigate the interactions between tumor microenvironment cells. METHODS: The red fluorescent protein-SU3 (SU3-RFP) or SU3 glioma stem cells (GSC) were inoculated into the brain, liver, abdominal cavity, and subcutis of green fluorescent protein (GFP)-nude mice. The tumor tissues were taken to observe the tissue cell distribution...
November 10, 2018: Journal of Cancer Research and Clinical Oncology
Jie Zhang, Chan Xiang, Yuchen Han, Haohua Teng, Xiaojing Li, Jinchen Shao, Lei Zhu, Han Han-Zhang, Junyi Ye, Keke Yu
PURPOSE: Pulmonary enteric adenocarcinoma (PEAC), defined as tumors with an enteric component exceeding 50% and a histological morphology similar to colorectal cancer (CRC) and metastatic colorectal carcinoma (MCC), is an extremely rare primary lung adenocarcinoma, which was recently recognized by World Health Organization (WHO). Adenocarcinomas with intestinal differentiation have also been described in other anatomic sites, including paranasal sinuses, extrahepatic biliary tree, uterine and cervix, ovary...
November 10, 2018: Journal of Cancer Research and Clinical Oncology
Anna Hester, Manuel Ritzer, Christina Kuhn, Elisa Schmoeckel, Doris Mayr, Thomas Kolben, Christian Dannecker, Sven Mahner, Udo Jeschke, Theresa Maria Kolben
PURPOSE: Prostaglandin-mediated inflammatory reactions play a major role in different cancers. Prostaglandin E2-receptor 3 (EP3) expression correlates with FIGO stages in cervical cancer and has been shown to be an independent prognostic factor for overall survival. EP3 expression levels in cervical intraepithelial neoplasia (CIN) as the precursor lesion of cervical cancer are currently unknown. METHODS: EP3 expression was analyzed by immunohistochemistry in 124 patient samples (CIN 1-3 and healthy controls) using the IR-scoring system...
November 7, 2018: Journal of Cancer Research and Clinical Oncology
Filippo Alongi, Alba Fiorentino, Fabiana Gregucci, Stefanie Corradini, Niccolo Giaj-Levra, Luigi Romano, Michele Rigo, Francesco Ricchetti, Alberto Beltramello, Gianluigi Lunardi, Rosario Mazzola, Ruggero Ruggieri
INTRODUCTION: Radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT) is increasing in the treatment of brain metastases (BMs). Aim of the present study was to evaluate the safety and effectiveness of SRS/SFRT for BMs, using a new mono-isocenter non-coplanar solution (HyperArc™ Varian Medical System). METHODS: BMs patients with a diameter inferior to 3 cm, a life expectancy of more than 3 months and a good performance status, were eligible for Linac-based volumetric modulated arc therapy (VMAT) SFRT/SRS with HyperArc™...
October 31, 2018: Journal of Cancer Research and Clinical Oncology
Karl R Aigner, Emir Selak, Kornelia Aigner
PURPOSE: Head and neck cancer treatment achieves good locoregional tumor control rates while causing severe side effects. Therapy with chemotherapeutic drugs administered intravenously is limited because either the concentrations at the tumor site are too low or the total dosages are too high. The evaluation of a technique for short-term intra-arterial infusion chemotherapy is described herein. METHODS: In a retrospective study, we reviewed the medical records of 97 patients with head and neck cancers who received short-term intra-arterial infusion chemotherapy (62 patients previously untreated, 35 patients with prior radiotherapy)...
October 31, 2018: Journal of Cancer Research and Clinical Oncology
Beata Jagielska, Elzbieta Sarnowska, Nataliia Rusetska, Iga Jancewicz, Monika Durzynska, Szymon Kubala, Ewa Chmielik, Piotr Paul, Tomasz Rutkowski, Tomasz J Sarnowski, Janusz A Siedlecki
PURPOSE: Adenoid cystic carcinoma (ACC) is a rare neurotropic cancer with slow progression occurring in salivary glands and less frequently in other body parts. ACC is featured by hyperchromatic nuclei and various mutations in genes encoding chromatin-related machineries. The ACC treatment is mainly limited to the radical surgery and radiotherapy while the chemotherapy remains ineffective. As the knowledge about molecular basis of ACC development is limited, we investigated here the molecular features of this disease...
October 31, 2018: Journal of Cancer Research and Clinical Oncology
Fabian Finkelmeier, Carolin Czauderna, Lukas Perkhofer, Thomas J Ettrich, Jörg Trojan, Arndt Weinmann, Jens U Marquardt, Johannes Vermehren, Oliver Waidmann
INTRODUCTION: Nivolumab is the first checkpoint-inhibitor approved for the treatment of advanced HCC patients. Real-life experience data of nivolumab treatment in HCC patients, especially those with advanced liver disease, is scarce. MATERIALS AND METHODS: All patients with confirmed advanced HCC and nivolumab treatment from three large German centers were retrospectively analyzed. Clinical parameters and outcome were assessed. RESULTS: A total of 34 patients were included...
October 29, 2018: Journal of Cancer Research and Clinical Oncology
Fa Zhang, Zhonglin Cai, Haidi Lv, Wenjuan Li, Mengtian Liang, Xupan Wei, Fenghai Zhou
PURPOSE: Human embryonic lethal abnormal visual-like protein, HuR, belongs to a member of the Hu family of RNA-binding protein and plays a critical role in urinary tumors. The purpose of this review is to summarize the current literature to demonstrate the importance of HuR in urinary tract tumors' biology and explore the potential role in therapeutic strategies aimed at targeting this molecule in cancer cells. METHODS: The relevant literature from PubMed and Medline databases is reviewed in this article...
October 28, 2018: Journal of Cancer Research and Clinical Oncology
Jacek Kordiak, Janusz Szemraj, Izabela Grabska-Kobylecka, Piotr Bialasiewicz, Marcin Braun, Radzisław Kordek, Dariusz Nowak
PURPOSE: Mutated KRAS oncogene in exhaled breath condensate (EBC) can be a genetic marker of non-small cell lung cancer (NSCLC). However, a possibility of inhomogeneous distribution in cancer tissue and intratumor heterogeneity of KRAS mutation may decrease its significance. We investigated a status of KRAS point mutation and its sequence at codon 12 in 51 NSCLC patients after tumor resection. The comparison of KRAS mutation status between EBC-DNA and cancer tissue was performed in 19 cases...
October 27, 2018: Journal of Cancer Research and Clinical Oncology
Steffen Rausch, Daniel Schollenberger, Joerg Hennenlotter, Viktoria Stühler, Stephan Kruck, Arnulf Stenzl, Jens Bedke
PURPOSE: Impaired regulation of the Akt/mammalian target of rapamycin (mTOR) pathway has been implicated in mechanisms related to neoplastic transformation in renal cell cancer (RCC) through enhancement of cell proliferation and survival and mTOR activation has been reported to occur due to phosphorylation of mTOR. To further determine the relevance of mTOR expression and activation and to analyze their putative role as a biomarker for systemic treatment in metastatic RCC, we investigated the expression of mTOR and phospho(p)-mTOR in primary RCC and metastases and correlated levels with pathological variables and clinical outcome...
October 27, 2018: Journal of Cancer Research and Clinical Oncology
Miroslawa Cichorek, Anna Ronowska, Monika Gensicka-Kowalewska, Milena Deptula, Iwona Pelikant-Malecka, Krystyna Dzierzbicka
PURPOSE: As a continuation of our search for anticancer agents, we have synthesized a new acridine-retrotuftsin analog HClx9-[Arg(NO2 )-Pro-Lys-Thr-OCH3 ]-1-nitroacridine (named ART) and have evaluated its activity against melanoma and neuroblastoma lines. Both tumors develop from cells (melanocytes, neurons) of neuroectodermal origin, and both are tumors with high heterogeneity and unsatisfactory susceptibility to chemotherapies. Thus, we analyzed the action of ART on pairs of biological forms of melanoma (amelanotic and melanotic) and neuroblastoma (dopaminergic and cholinergic) with regard to proliferation, mechanism of cell death, and effect on the activity of tricarboxylic acid cycle (TAC) enzymes...
October 26, 2018: Journal of Cancer Research and Clinical Oncology
Jonathan Gootee, Sarah Aurit, Christina Curtin, Peter Silberstein
BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is a high-grade, clinically aggressive tumor associated with low survival probabilities. Prognostic variables for DDLPS have not been previously reported in a large patient population. METHODS: A total of 3573 patients with primary DDLPS were analyzed from the National Cancer Data Base (NCDB). The 5- and 10-year survival probabilities were calculated, and the groups were compared using log-rank comparisons and multivariable Cox hazard regression analysis...
October 25, 2018: Journal of Cancer Research and Clinical Oncology
Chang Liu, Zhi Li, Shuo Wang, Yibo Fan, Simeng Zhang, Xianghong Yang, Kezuo Hou, Jianhua Tong, Xuejun Hu, Xiaonan Shi, Xiaoxun Wang, Yunpeng Liu, Xiaofang Che, Xiujuan Qu
PURPOSE: As an important glycosyltransferase, fucosyltransferase IV (FUT4) is abnormally upregulated in different types of cancers, but its clinical role remains inexplicit. This work aimed to determine the predictive ability of FUT4 in lung adenocarcinoma (LUAD) after curative resection, as well as to explore the role of a possible FUT4 molecular mechanism on LUAD malignant behavior. METHODS: A total of 273 LUAD patients after curative resection with complete clinicopathological and RNAseq data from The Cancer Genome Atlas (TCGA) cohort were collected...
October 24, 2018: Journal of Cancer Research and Clinical Oncology
Simona Camero, Simona Ceccarelli, Francesca De Felice, Francesco Marampon, Olga Mannarino, Lucrezia Camicia, Enrica Vescarelli, Paola Pontecorvi, Barry Pizer, Rajeev Shukla, Amalia Schiavetti, Maria Giovanna Mollace, Antonio Pizzuti, Vincenzo Tombolini, Cinzia Marchese, Francesca Megiorni, Carlo Dominici
PURPOSE: PARP inhibitors (PARPi) are used in a wide range of human solid tumours but a limited evidence is reported in rhabdomyosarcoma (RMS), the most frequent childhood soft-tissue sarcoma. The cellular and molecular effects of Olaparib, a specific PARP1/2 inhibitor, and AZD2461, a newly synthesized PARP1/2/3 inhibitor, were assessed in alveolar and embryonal RMS cells both as single-agent and in combination with ionizing radiation (IR). METHODS: Cell viability was monitored by trypan blue exclusion dye assays...
October 24, 2018: Journal of Cancer Research and Clinical Oncology
Lara Elis Alberici Delsin, Karina Bezerra Salomao, Julia Alejandra Pezuk, Maria Sol Brassesco
Current cure rates for retinoblastoma (RB) are very high in developed countries. Nonetheless, in less privileged places worldwide, delayed diagnosis and refusal to adhere to treatment still endure an obstacle to improve overall patient survival. Thus, the access to consistent biomarkers for diagnosis at an earlier stage may facilitate treatment and improve outcomes. Over recent years, much attention has been focused on miRNAs, key post-transcriptional regulators that when altered, largely contribute to carcinogenesis and tumor progression...
October 22, 2018: Journal of Cancer Research and Clinical Oncology
Zhen Wang, Xiao Chen, Yongqiang Zhao, Yi Jin, Jia Zheng
BACKGROUND: Emerging evidences show that G-protein-coupled estrogen receptor (GPER) can regulate the progression of various cancers, while its roles in the progression of osteosarcoma (OS) are not well illustrated. METHODS: The expression of GPER in OS cells and tissues were checked. Its roles in cell migration and expression of Snail was checked by use of its agonist G-1. RESULTS: We found that the expression of GPER in OS cells and tissues were lower than that in their corresponding controls...
October 20, 2018: Journal of Cancer Research and Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"